Polymorphic forms of ST-246 and methods of preparation
Inventors
Tyavanagimatt, Shanthakumar R. • Stone, Melialani A. C. L. • Weimers, William C. • Nelson, Dylan • Bolken, Tove′ C. • Hruby, Dennis E. • O'Neill, Michael H. • Sweetapple, Gary • McCloughan, Kelley A.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
Core Innovation
The content describes ST-246 polymorph Form I as a monohydrate identified by a characteristic X-ray powder diffraction pattern with specific reflection peaks. The disclosure reports powder X-ray diffraction traces, comparative diffraction patterns, and annotated FTIR spectra that support the identification of Form I. It also reports isolated-form purity, pharmaceutical compositions containing the polymorph, and oral capsule formulations.
The content further describes dissolution profiles over 0–60 minutes, faster dissolution for smaller Form I particles, and an ST-246 concentration-time profile over 72 hours. It reports preparation of Form I [procedural detail omitted for safety] and reliable production at greater than 99% purity. The polymorph is characterized as thermodynamically stable and non-hygroscopic, while the background and problem solved are not explicitly described in patent.
Claims Coverage
The claims identify one independent claim comprising one inventive feature directed to ST-246 polymorph Form I distinguished by characteristic X-ray powder diffraction peaks.
ST-246 polymorph Form I characterized by X-ray powder diffraction
The independent claim covers polymorph Form I of ST-246 characterized by an X-ray powder diffraction pattern having specified characteristic reflection peaks.
The independent claim defines ST-246 polymorph Form I by its characteristic diffraction pattern, while dependent claims add purity limitations, pharmaceutical compositions for oral administration, and a production method [procedural detail omitted for safety].
Stated Advantages
Form I is reported to be thermodynamically stable and non-hygroscopic.
The form is reported to be reliably produced at greater than 99% purity.
Smaller Form I particles are reported to provide faster dissolution.
Documented Applications
Form I is used in pharmaceutical compositions comprising one or more pharmaceutically acceptable ingredients and formulated for oral administration, including oral capsules.
Interested in licensing this patent?